Immunotherapy Making Its Mark on Head and Neck Cancer
Author: Lisa Miller Published online: 03/22/2017 Source: http://www.targetedonc.com/ Following the approval of 2 immunotherapy agents, pembrolizumab (Keytruda) and nivolumab (Opdivo) for the treatment of patients with head and neck cancer (HNC) over the last 6 months, immunotherapy is making its mark on the treatment paradigm for HNC. Due to the responses seen with these 2 agents, immunotherapies are being